Effects of an angiotensin-converting enzyme inhibitor and a β-blocker on cerebral arterioles in rats

被引:51
|
作者
Chillon, JM
Baumbach, GL
机构
[1] Univ Iowa, Coll Med, Dept Pathol, Med Labs 100, Iowa City, IA 52242 USA
[2] Univ Iowa, Ctr Cardiovasc, Iowa City, IA 52242 USA
关键词
hypertension; chronic; vascular remodeling; angiotensin; hypertrophy; vascular;
D O I
10.1161/01.HYP.33.3.856
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
We examined the effects of an angiotensin-converting enzyme inhibitor, perindopril, and a beta-blocker, propranolol, on cerebral arterioles in stroke-prone spontaneously hypertensive rats (SHRSP). The structure and mechanics of cerebral arterioles were examined in untreated Wistar-Kyoto rats (WKY) and SHRSP that were untreated or treated for 3 months with a high (2 mg/kg per day) or a low (0.3 mg/kg per day) dose of perindopril or propranolol (250 mg/kg per day) alone or in combination with the low dose of perindopril. We measured pressure, external diameter, and cross-sectional area of the vessel wall (CSA) in maximally dilated (with EDTA) cerebral arterioles. Treatment of SHRSP with the high dose of perindopril or the combination of propranolol and the low dose of perindopril normalized cerebral arteriolar mean pressure (50+/-1 [mean+/-SEM] and 43+/-2 mm Hg vs 50+/-1 mm Hg in WKY and 94+/-3 mm Hg in untreated SHRSP; P<0.05), pulse pressure (15+/-1 and 16+/-1 mm Hg vs 13+/-1 mm Hg in WKY and 35+/-1 mm Hg in untreated SHRSP; P<0.05), and CSA (1103+/-53 and 1099+/-51 mu m(2), respectively, vs 1057+/-49 mu m(2) in WKY and 1281+/-67 mu m(2) in untreated SHRSP; P<0.05). In contrast, treatment of SHRSP with the law dose of perindopril or propranolol alone did not normalize arteriolar pulse pressure (24+/-1 and 21+/-1 mm Hg) and failed to prevent increases in CSA (1282+/-77 and 1267+/-93 mu m(2)). Treatment with either dose of perindopril or the combination of propranolol and perindopril significantly increased external diameter in cerebral arterioles of SHRSP (99+/-3, 103+/-2, and 98+/-3 mu m vs 87+/-2 mu m in untreated SHRSP; P<0.05), whereas propranolol alone did not (91+/-3 mu m; P>0.05). These findings suggest that effects of angiotensin-converting enzyme inhibitors on cerebral arteriolar hypertrophy in SHRSP map depend primarily on their effects on arterial pressure, particularly pulse pressure, whereas their effects on cerebral arteriolar remodeling (defined as a reduction in external diameter) may be pressure independent.
引用
收藏
页码:856 / 861
页数:6
相关论文
共 50 条
  • [31] Angiotensin-converting enzyme and vascular remodeling
    Heeneman, Sylvia
    Sluimer, Judith C.
    Daemen, Mat J. A. P.
    CIRCULATION RESEARCH, 2007, 101 (05) : 441 - 454
  • [32] Non-corresponding effects of an angiotensin-converting enzyme inhibitor on cardiac and vascular hypertrophy in spontaneously hypertensive rats
    Tozawa, M
    Takishita, S
    Muratani, H
    Fukiyama, K
    HYPERTENSION RESEARCH, 2000, 23 (05) : 483 - 490
  • [33] Cough in Pediatric Patients Receiving Angiotensin-Converting Enzyme Inhibitor Therapy or Angiotensin Receptor Blocker Therapy in Randomized Controlled Trials
    Baker-Smith, C. M.
    Benjamin, D. K., Jr.
    Califf, R. M.
    Murphy, M. D.
    Li, J. S.
    Smith, P. B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (06) : 668 - 671
  • [34] Angiotensin-Converting Enzyme Inhibitor Does Not Suppress Renal Angiotensin II Levels in Angiotensin I-Infused Rats
    Ohnishi, Keisuke
    Murase, Miki
    Nakano, Daisuke
    Pelisch, Nicolas
    Hitomi, Hirofumi
    Kobori, Hiroyuki
    Morimoto, Satoshi
    Mori, Hirohito
    Masaki, Tsutomu
    Ohmori, Koji
    Kohno, Masakazu
    Ichihara, Atsuhiro
    Nishiyama, Akira
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2013, 122 (02) : 103 - 108
  • [35] Comparison of Effects of Low Dose of Spironolactone and a Thiazide Diuretic in Patients with Hypertension Treated with an Angiotensin-Converting Enzyme Inhibitor or an Angiotensin Type 1 Receptor Blocker
    Yutaka, Miyashita
    Mifune, Mizuo
    Kubota, Eiji
    Itoh, Hiroshi
    Saito, Ikuo
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2009, 31 (08) : 648 - 656
  • [36] Myocardial Laminar Organization Is Retained in Angiotensin-Converting Enzyme Inhibitor Treated SHRs
    Wilson, A. J.
    Sands, G. B.
    Wang, V. Y.
    Hasaballa, A., I
    Pontre, B.
    Young, A. A.
    Nash, M. P.
    LeGrice, I. J.
    EXPERIMENTAL MECHANICS, 2021, 61 (01) : 31 - 40
  • [37] Haemodynamic effects of an angiotensin-converting enzyme inhibitor and angiotensin receptor antagonist during hypovolaemia in the anaesthetized pig
    Ryckwaert, F
    Colson, P
    André, E
    Perrigault, PF
    Guillon, G
    Barberis, C
    BRITISH JOURNAL OF ANAESTHESIA, 2002, 89 (04) : 599 - 604
  • [38] Angiotensin-converting enzyme inhibitors
    Brown, NJ
    Vaughan, DE
    CIRCULATION, 1998, 97 (14) : 1411 - 1420
  • [39] Genetic influences of angiotensin-converting enzyme inhibitor response: an opportunity for personalizing therapy?
    Brugts, Jasper J.
    Simoons, Maarten L.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2012, 10 (08) : 1001 - 1009
  • [40] Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2
    Ferrario, CM
    Jessup, J
    Chappell, MC
    Averill, DB
    Brosnihan, KB
    Tallant, EA
    Diz, DI
    Gallagher, PE
    CIRCULATION, 2005, 111 (20) : 2605 - 2610